Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs

IB Adams, W Ryan, M Singer, BF Thomas, DR Compton, RK Razdan and BR Martin

Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, USA.

Recent evidence implicates anandamide as the endogenous ligand for the cannabinoid receptor. One purpose of this study was to determine the structural requirements for anandamide's receptor interaction and the influence of phenylmethylsulfonyl fluoride (PMSF), an enzyme inhibitor, on receptor affinity. A second objective was evaluation of the correlation between affinities of the analogs and in vivo pharmacological activities. The ability of anandamide and analogs to displace [3H]CP-55,940 ([3](-)-3-[2-hydroxyl-4-(1,1- dimethylheptyl)phenyl]-4-[3- hydroxylpropyl]cyclohexan-1-ol) was determined by a filtration assay. Displacement curves for anandamide in the presence of PMSF produced a Ki of 89 +/- 10 nM; without PMSF the Ki increased to 5400 +/- 1600 nM. Anandamide analogs were evaluated for their ability to produce antinociception and hypomotility. The levels of saturation of the anandamide structure were critical to receptor affinity and in vivo potency, with complete saturation and hydroxyl substitution with a fluorine moiety resulting in a compound with increased potency in the spontaneous activity and antinociception assays. Substitution of the hydroxyl with a fluorine atom increased affinity only in the presence of PMSF and reduced potency in the antinociception assay. Ethanolamide substitution with bromobenzenesulfonamide produced an inactive compound in all assays. Increasing the length of the N-substituent by one or two carbons decreased receptor binding affinity and potency in the tail-flick assay only. Certain structural modifications, such as methylations, allowed the analogs to retain affinity without the addition of PMSF. Linear correlation between the behavioral and binding assays were performed, and the greatest correlation was obtained with compounds that were either very potent or inactive.

Volume 273, Issue 3, pp. 1172-1181, 06/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				S. Akerman, P. R. Holland, and P. J. Goadsby Cannabinoid (CB1) Receptor Activation Inhibits Trigeminovascular Neurons J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 64 - 71. [Abstract] [Full Text] [PDF]

				S. Akerman, H. Kaube, and P. J. Goadsby Anandamide Is Able to Inhibit Trigeminal Neurons Using an in Vivo Model of Trigeminovascular-Mediated Nociception J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 56 - 63. [Abstract] [Full Text]

				C. Y. Baskfield, B. R. Martin, and J. L. Wiley Differential Effects of {Delta}9-Tetrahydrocannabinol and Methanandamide in CB1 Knockout and Wild-Type Mice J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 86 - 91. [Abstract] [Full Text]

				Y. Segall, G. B. Quistad, S. E. Sparks, D. K. Nomura, and J. E. Casida Toxicological and Structural Features of Organophosphorus and Organosulfur Cannabinoid CB1 Receptor Ligands Toxicol. Sci., November 1, 2003; 76(1): 131 - 137. [Abstract] [Full Text] [PDF]

				J. L. Wiley, I. D. Beletskaya, E. W. Ng, Z. Dai, P. J. Crocker, A. Mahadevan, R. K. Razdan, and B. R. Martin Resorcinol Derivatives: A Novel Template for the Development of Cannabinoid CB1/CB2 and CB2-Selective Agonists J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 679 - 689. [Abstract] [Full Text] [PDF]

				C. S. Breivogel, G. Griffin, V. Di Marzo, and B. R. Martin Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain Mol. Pharmacol., July 1, 2001; 60(1): 155 - 163. [Abstract] [Full Text]

				J. L. Wiley, R. G. Jefferson, M. C. Grier, A. Mahadevan, R. K. Razdan, and B. R. Martin Novel Pyrazole Cannabinoids: Insights into CB1 Receptor Recognition and Activation J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 1013 - 1022. [Abstract] [Full Text]

				B. R. Martin, I. Beletskaya, G. Patrick, R. Jefferson, R. Winckler, D. G. Deutsch, V. Di Marzo, O. Dasse, A. Mahadevan, and R. K. Razdan Cannabinoid Properties of Methylfluorophosphonate Analogs J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1209 - 1218. [Abstract] [Full Text]

				B.C. Paria, X. Zhao, J. Wang, S.K. Das, and S.K. Dey Fatty-Acid Amide Hydrolase Is Expressed in the Mouse Uterus and Embryo during the Periimplantation Period Biol Reprod, May 1, 1999; 60(5): 1151 - 1157. [Abstract] [Full Text]

				M. D. Aceto, S. M. Scates, R. K. Razdan, and B. R. Martin Anandamide, an Endogenous Cannabinoid, Has a Very Low Physical Dependence Potential J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 598 - 605. [Abstract] [Full Text]

				G. Griffin, P. J. Atkinson, V. M. Showalter, B. R. Martin, and M. E. Abood Evaluation of Cannabinoid Receptor Agonists and Antagonists Using the Guanosine-5'-O-(3-[35S]thio)-triphosphate Binding Assay in Rat Cerebellar Membranes J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 553 - 560. [Abstract] [Full Text]

				Q. Tao and M. E. Abood Mutation of a Highly Conserved Aspartate Residue in the Second Transmembrane Domain of the Cannabinoid Receptors, CB1 and CB2, Disrupts G-Protein Coupling J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 651 - 658. [Abstract] [Full Text]

				D. L. Boger, J. E. Patterson, X. Guan, B. F. Cravatt, R. A. Lerner, and N. B. Gilula Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide PNAS, April 28, 1998; 95(9): 4810 - 4815. [Abstract] [Full Text] [PDF]

				B. F. Thomas, A. F. Gilliam, D. F. Burch, M. J. Roche, and H. H. Seltzman Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 285 - 292. [Abstract] [Full Text]

				I. B. Adams, D. R. Compton, and B. R. Martin Assessment of Anandamide Interaction with the Cannabinoid Brain Receptor: SR 141716A Antagonism Studies in Mice and Autoradiographic Analysis of Receptor Binding in Rat Brain J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 1209 - 1217. [Abstract] [Full Text]

				D. R. Compton and B. R. Martin The Effect of the Enzyme Inhibitor Phenylmethylsulfonyl Fluoride on the Pharmacological Effect of Anandamide in the Mouse Model of Cannabimimetic Activity J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1138 - 1143. [Abstract] [Full Text]

				K. A. Willoughby, S. F. Moore, B. R. Martin, and E. F. Ellis The Biodisposition and Metabolism of Anandamide in Mice J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 243 - 247. [Abstract] [Full Text]

				K. D. Lake, B. R. Martin, G. Kunos, and K. Varga Cardiovascular Effects of Anandamide in Anesthetized and Conscious Normotensive and Hypertensive Rats Hypertension, May 1, 1997; 29(5): 1204 - 1210. [Abstract] [Full Text]